Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin.

Lebensburger JD, Howard T, Hu Y, Pestina TI, Gao G, Johnson M, Zakharenko SS, Ware RE, Tuomanen EI, Persons DA, Rosch JW.

Blood. 2012 Feb 23;119(8):1915-21. doi: 10.1182/blood-2011-08-374447.

2.

Hydroxyurea makes inflammation "just right"?

Hsu LL.

Blood. 2012 Feb 23;119(8):1796-8. doi: 10.1182/blood-2011-12-397794. Erratum in: Blood. 2014 Jan 30;123(5):798.

3.

Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice.

Almeida CB, Scheiermann C, Jang JE, Prophete C, Costa FF, Conran N, Frenette PS.

Blood. 2012 Oct 4;120(14):2879-88. doi: 10.1182/blood-2012-02-409524.

4.

Hydroxyurea therapy: improving the lives of patients with sickle cell disease.

Anderson N.

Pediatr Nurs. 2006 Nov-Dec;32(6):541-3. Review.

PMID:
17256291
5.

Hydroxyurea corrects the dysregulated L-selectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia.

Benkerrou M, Delarche C, Brahimi L, Fay M, Vilmer E, Elion J, Gougerot-Pocidalo MA, Elbim C.

Blood. 2002 Apr 1;99(7):2297-303.

6.
7.

Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.

Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M.

JAMA. 2003 Apr 2;289(13):1645-51. Erratum in: JAMA. 2003 Aug 13;290(6):756.

PMID:
12672732
8.

Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.

Medicine (Baltimore). 1996 Nov;75(6):300-26.

9.

Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease.

Gordeuk VR, Campbell A, Rana S, Nouraie M, Niu X, Minniti CP, Sable C, Darbari D, Dham N, Onyekwere O, Ammosova T, Nekhai S, Kato GJ, Gladwin MT, Castro OL.

Blood. 2009 Nov 19;114(21):4639-44. doi: 10.1182/blood-2009-04-218040.

10.

Hydroxyurea therapy in children severely affected with sickle cell disease.

Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ.

J Pediatr. 1996 Jun;128(6):820-8.

PMID:
8648542
11.

Hydroxyurea with AKT2 inhibition decreases vaso-occlusive events in sickle cell disease mice.

Barazia A, Li J, Kim K, Shabrani N, Cho J.

Blood. 2015 Nov 26;126(22):2511-7. doi: 10.1182/blood-2015-02-626234.

12.

Hydroxyurea in the treatment of sickle-cell anemia.

Howard LW, Kennedy LD.

Ann Pharmacother. 1997 Nov;31(11):1393-6. Review.

PMID:
9391697
13.

Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea.

Green NS, Ender KL, Pashankar F, Driscoll C, Giardina PJ, Mullen CA, Clark LN, Manwani D, Crotty J, Kisselev S, Neville KA, Hoppe C, Barral S.

PLoS One. 2013;8(2):e55709. doi: 10.1371/journal.pone.0055709.

14.

Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.

Okam MM, Ebert BL.

Expert Rev Hematol. 2012 Jun;5(3):303-11. doi: 10.1586/ehm.12.20. Review.

PMID:
22780210
15.

Effect of hydroxyurea therapy on resting energy expenditure in children with sickle cell disease.

Fung EB, Barden EM, Kawchak DA, Zemel BS, Ohene-Frempong K, Stallings VA.

J Pediatr Hematol Oncol. 2001 Dec;23(9):604-8.

PMID:
11902305
16.

Long-term use of hydroxyurea for sickle cell anemia.

Hagar W.

JAMA. 2003 Aug 13;290(6):753; author reply 754. No abstract available.

PMID:
12915424
17.

Key endothelial cell angiogenic mechanisms are stimulated by the circulating milieu in sickle cell disease and attenuated by hydroxyurea.

Lopes FC, Traina F, Almeida CB, Leonardo FC, Franco-Penteado CF, Garrido VT, Colella MP, Soares R, Olalla-Saad ST, Costa FF, Conran N.

Haematologica. 2015 Jun;100(6):730-9. doi: 10.3324/haematol.2014.119727.

18.

Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.

Koren A, Segal-Kupershmit D, Zalman L, Levin C, Abu Hana M, Palmor H, Luder A, Attias D.

Pediatr Hematol Oncol. 1999 May-Jun;16(3):221-32.

PMID:
10326220
19.

[Effect of hydroxyurea on hemoglobin S].

Torres AF, Eberle SE, Sciuccati G, Bonduel M.

Medicina (B Aires). 2003;63(2):140-2. Spanish.

PMID:
12793083
20.

Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia.

Covas DT, de Lucena Angulo I, Vianna Bonini Palma P, Zago MA.

Haematologica. 2004 Mar;89(3):273-80.

Supplemental Content

Support Center